Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PITTSBURGH, Aug. 1, 2013 /PRNewswire/ – Mylan Inc. (NYSE:MYL) today announced its financial results for the three and six months ended June 30, 2013.
Financial Highlights
•Adjusted diluted EPS of $0.68 for the three months ended June 30, 2013 compared to $0.60 for the same prior year period, an increase of 13%
•Total revenues of $1.70 billion for the three months ended June 30, 2013 compared to $1.69 billion for the same prior year period, an increase of 1%. On a constant currency basis and excluding the impact of Escitalopram in both periods, total revenues would have increased approximately 10%
Help employers find you! Check out all the jobs and post your resume.
PITTSBURGH, Aug. 1, 2013 /PRNewswire/ – Mylan Inc. (NYSE:MYL) today announced its financial results for the three and six months ended June 30, 2013.
Financial Highlights
•Adjusted diluted EPS of $0.68 for the three months ended June 30, 2013 compared to $0.60 for the same prior year period, an increase of 13%
•Total revenues of $1.70 billion for the three months ended June 30, 2013 compared to $1.69 billion for the same prior year period, an increase of 1%. On a constant currency basis and excluding the impact of Escitalopram in both periods, total revenues would have increased approximately 10%
Help employers find you! Check out all the jobs and post your resume.
